Table 4.
Comparison of demographic and clinical characteristics of PSV patients between ever and never smokers
| Variables | Ever smokers (N=27) | Never smokers (N=99) | P* |
| Age | 54.85±13.9 | 46.99±16.8 | 0.028 |
| Sex (Female/Male) | 3/24 | 67/32 | 0.0001 |
| General symptoms (%) | 19 (70.4) | 55 (55.6) | 0.128 |
| Cutaneous involvement/Mucous membranes (%) | 12 (44.4) | 45 (45.6) | 0.517 |
| Ophthalmic involvement (%) | 3 (11.1) | 7 (7.1) | 0.356 |
| Ears, nose, throat involvement (%) | 9 (33.3) | 17 (17.1) | 0.068 |
| Pulmonary involvement (%) | 8 (29.6) | 17 (17.2) | 0.123 |
| Cardiovascular system involvement (%) | 4 (14.8) | 15 (15.2) | 0.602 |
| Abdominal involvement (%) | 2 (7.4) | 4 (4.0) | 0.389 |
| Renal involvement (%) | 11 (40.7) | 29 (29.3) | 0.201 |
| Nervous system involvement (%) | 9 (33.3) | 32 (32.3) | 0.147 |
| BVAS at the baseline | 13.96±8.9 | 9.69±5.8 | 0.020 |
| VDI at the baseline | 0 (0-3) | 0 (0-3) | 0.632 |
| VDI at the last visit | 0 (0-3) | 1 (0-4) | 0.595 |
| Patients with disease in remission | 23 (33.3) | 89 (35.5) | 0.540 |
PSV: primary systemic vasculitides; BVAS: Birmingham Vasculitis Activity Score; VDI: Vasculitis Damage Index.
Data were displayed as numbers (percentages), means ± SD, or median (Min-Max), as appropriate.
P< 0.05 was considered significant.
* P values indicate comparison between groups (Chi squared, Independent-sample t test or Mann–Whitney U test, as appropriate)